Assessment of HPV-mRNA test to predict recurrent disease in patients previously treated for CIN 2/3

Journal of Clinical Virology

Volumn 60, Issue 1, 2014, Pages 39-43

  Frega, Antonio ^a   Sesti, Francesco ^b   Lombardi, Danila ^a   Votano, Sergio ^c   Sopracordevole, Francesco ^d   Catalano, Angelica ^a   Milazzo, Giusi Natalia ^a   Lombardo, Riccardo ^a   Assorgi, Chiara ^a   Olivola, Sara ^b   Chiusuri, Valentina ^b   Ricciardi, Enzo ^a   French, Deborah ^a   Moscarini, Massimo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^c LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^d CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

CIN 2 3; HPV mRNA test; Recurrence; Residual disease

Indexed keywords

VIRUS DNA; VIRUS MESSENGER RNA; MESSENGER RNA; VIRUS RNA;

ADULT; ARTICLE; CANCER RECURRENCE; COHORT ANALYSIS; COLPOSCOPE; COLPOSCOPY; COMPARATIVE STUDY; CYTOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS MESSENGER RNA TEST; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN TISSUE; LOOP ELECTROSURGICAL EXCISION PROCEDURE; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MOLECULAR DIAGNOSTICS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OUTCOME ASSESSMENT; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT DISEASE; SENSITIVITY AND SPECIFICITY; SURGICAL EQUIPMENT; SURGICAL TECHNIQUE; UNIVARIATE ANALYSIS; UTERINE CERVIX CARCINOMA IN SITU; VIRAL CLEARANCE; WART VIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; CLINICAL TRIAL; EVALUATION STUDY; GENETICS; MIDDLE AGED; MOLECULAR DIAGNOSIS; MULTICENTER STUDY; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTIONS; PROCEDURES; VIROLOGY;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; COHORT STUDIES; FEMALE; HUMANS; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROSPECTIVE STUDIES; RECURRENCE; RNA, MESSENGER; RNA, VIRAL; SENSITIVITY AND SPECIFICITY;

EID: 84899047670     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2014.01.017     Document Type: Article

References (26)

1. ZurHausen H. Papillomavirus and cancer: from basic studies to clinical application. Nat Rev Cancer 2002, 2(5):342-350.
2. Alonso I., Torné A., Puig-Tintoré L.M., Esteve R., Quinto L. High-risk cervical intraepithelial neoplasia grade 1 treated by loop electrosurgical excision procedure: follow-up and value of HPV testing. Am J Obstet Gynecol 2007, 197:359.e1-359.e6.
3. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12-19.
4. Paraskevaidis E., Koliopoulos G., Alamanos Y., Malamou-Mitsi V., Lolis E.D., Kitchener H.C. Human papillomavirus testing and the outcome of treatment for cervical intraepithelial neoplasia. Obstet Gynecol 2001, 98:833-836.
5. Arbyn M., Sasieni P., Meijer C.J., Clavel C., Koliopoulos G., Dillner J. Chapter 9: clinical applications of HPV testing: a summary meta-analysis. Vaccine 2006, 24:89.
6. Zielinski G.D., Bais A.G., HelmerHorst T.J., Verheijen R.H., de Schipper F.A., Snijders P.J., et al. HPV testing and monitoring of women after treatment of CIN 3: review of the literature and meta-analysis. Obstet Gynecol Surv 2004, 59:543-553.
7. Arbyn M., Paraskevaidis E., Martin-Hirsch P., Prendiville W., Dillner J. Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high grade CIN: an update of pulled evidence. Gynecol Oncol 2005, 99(3 (Suppl. 2)):s7-s11.
8. Brismar S., Johansson B., Borjesson M., Arbyn M., Andersson S. Follow-up after treatment of cervical intraepithelial neoplasia by human papillomavirus genotyping. Am J Obstet Gynecol 2009, 201:17e1-17e8.
9. Persson M., BrismarWendel S., Ljungblad L., Johansson B., Weiderpass E., Andersson S. High-risk human papillomavirus E6/E7 mRNA and L1 DNA as markers of residual/recurrent cervical intraepithelial neoplasia. Oncol Rep 2012, 28(1):346-352.
10. Burger E.A., Kornor H., Klemp M., Lauvrak V., Kristiansen I.S. HPV mRNA tests for the detection of cervical intraepithelial neoplasia: a systematic review. Gynecol Oncol 2011, 120:430-438.
11. Peitsaro P., Johansson B., Syrjanen S. Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique. J Clin Microbiol 2002, 40:886-891.
12. Jones J., Saleem A., Rai N., Shylasree T.S., Ashman S., Gregory K., et al. Human papillomavirus genotype testing combined with cytology as a "test of cure" post treatment: the importance of persistent viral infection. J Clin Virol 2011, 52(2):88-92.
13. Dowhanick J.J., McBride A.A., Howley P.M. Suppression of cellular proliferation by the papillomavirus E2 protein. J Virol 1995, 69:7791-7799.
14. Tropé A., Jonassen C.M., Sjøborg K.D., Nygård M., Dahl F.A., Alfsen G.C., et al. Role of high-risk human papillomavirus (HPV) mRNA testing in the prediction of residual disease after conisation for high-grade cervical intraepithelial neoplasia. Gynecol Oncol 2011, Nov, 123(2):257-262.
15. Zappacosta R., Ianieri M.M., Tinelli A., Gustapane S., D'Angelo C., Gatta D.M., et al. Detection of residual/recurrent cervical disease after successful LEEP conization: the possible role of mRNA-HPV test. Curr Pharm Des 2013, 19(8):1450-1457.
16. Lubrano A., Medina N., Benito V., Arencibia O., Falcón J.M., Leon L., et al. Follow-up after LLETZ: a study of 682 cases of CIN 2-CIN 3 in a single institution. Eur J Obstet Gynecol Reprod Biol 2012, 161(1):71-74.
17. Verguts J., Bronselaer B., Donders G., Arbyn M., Van E.J., Drijkoningen M., et al. Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conization. BJOG 2006, 113:1303-1307.
18. Dockter J., Schroder A., Hill C., Guzenski L., Monsonego J., Giachetti C. Clinical performance of the APTIMA HPV assay for the detection of high-risk HPV and high-grade cervical lesions. J Clin Virol 2009, 45:S55-S61.
19. French D., Lorenzon L. HPV infections: basis of neoplastic transformation and related molecular tests. Curr Pharm Des 2013, 19:1371-1378.
20. Moore B.C., Higgins R.V., Laurent S.L., Marroum M.C., Bellit B. Predictive factors from conization for residual cervical intraepithelial neoplasia. Am J Obstet Gynecol 1995, 173:361-368.
21. Nagai Y., Maehama T., Asato T., Kanazawa K. Persistence of human papillomavirus infection after therapeutic conization for CIN 3: is it an alarm for disease recurrence?. Gynecol Oncol 2000, 79:294-299.
22. Alonso I., Torne A., Piug-Tintoré L., Esteve R., Pahisa J., Ordo J. Pre- and post-conization high-risk HPV testing predicts residual/recurrent disease in patients treated for CIN 2-3. Gynecol Oncol 2006, 103:631-636.
23. Bollen L.J., Tjong-A-Hung S.P., van der Velden J. Prediction of recurrent and residual cervical dysplasia by human papillomavirus detection among patients with abnormal cytology. Gynecol Oncol 1999, 72:199-201.
24. Nuovo J., Melnikow J., Willan A.R., Chan B.K. Treatments outcomes for squamous intraepithelial lesions. Int J Gynaecol Obstet 2000, 68:25-33.
25. Murta F.C., Resende A.V., Souza M.A.H., Adad S.J., Salum R. Importance of surgical margins in conization for cervical intraepithelial neoplasia grade III. Arch Gynecol Obstet 1999, 263:42-44.
26. Ghaem-Maghami S., Sagi S., Majeed G., Soutter W.P. Incomplete excision of cervical intraepithelial neoplasia and risk of treatment failure: a meta-analysis. Lancet Oncol 2007 Nov, 8(11):985-993.